疾病
生物
胃肠道
免疫系统
肠道菌群
肝肠循环
脂肪肝
医学
免疫学
内科学
胆汁酸
内分泌学
作者
Jianchun Duan,Qinmei Li,Yan Cheng,Weifeng Zhu,Hongning Liu,Fei Li
出处
期刊:MedComm
[Wiley]
日期:2024-12-01
卷期号:5 (12)
摘要
Abstract Increasing evidences indicate that the gut microbiota is involved in the development and therapy of gastrointestinal and hepatic disease. Imbalance of gut microbiota occurs in the early stages of diseases, and maintaining the balance of the gut microbiota provides a new strategy for the treatment of diseases. It has been reported that Parabacteroides distasonis is associated with multiple diseases. As the next‐generation probiotics, several studies have demonstrated its positive regulation on the gastrointestinal and hepatic disease, including inflammatory bowel disease, colorectal cancer, hepatic fibrosis, and fatty liver. The function of P. distasonis and its metabolites mainly affect host immune system, intestinal barrier function, and metabolic networks. Manipulation of P. distasonis with natural components lead to the protective effect on enterohepatic disease. In this review, the metabolic pathways regulated by P. distasonis are summarized to illustrate its active metabolites and their impact on host metabolism, the role and action mechanism in gastrointestinal and hepatic disease are discussed. More importantly, the natural components can be used to manipulate P. distasonis as treatment strategies, and the challenges and perspectives of P. distasonis in clinical applications are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI